Patricia S. E.
- Country
- Spain
- Department
- Neumología
Research Overview
- Evaluation of Budesonide, Glycopyrronium Bromide, and Formoterol Fumarate on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease Patients
- Efficacy and Safety Evaluation of Tanimilast (CHF6001) as an Add-On to Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis
- Efficacy and Safety Evaluation of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease: A Phase III Randomized Controlled Trial
Data & Insights
Has run more than one trial at 71 of 369 partner sites.
Specializations
Respiratory Disease Management
This investigator specializes in treating Chronic Obstructive Pulmonary Disease (COPD), with particular emphasis on advanced therapeutic interventions and combination treatments.
- Triple Therapy Applications
- Bronchodilator Treatments
- Exacerbation Management
Their research interests extend to investigating innovative inhalation therapies and maintenance treatment strategies.
Therapeutic Innovation
The investigator focuses on evaluating novel therapeutic combinations for respiratory conditions, particularly in the context of metered-dose inhaler applications and long-term disease management.
- Combination Therapy Development
- Treatment Optimization
- Long-term Disease Control
Their work encompasses the assessment of various therapeutic combinations to enhance patient outcomes.
Clinical Outcomes
The investigator's expertise includes studying cardiopulmonary outcomes and the management of chronic bronchitis in COPD patients.
- Severe Outcome Prevention
- Disease Progression Management
- Treatment Efficacy Assessment
Their research contributes to understanding the effectiveness of various treatment approaches in respiratory care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.